Wire · opportunities
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
Thomas Jensen, experienced biotech CEO, has been appointed Chair of Valion Bio's Board to advance Entolimod, an investigational medical countermeasure for acute radiation syndrome, supported by significant government funding and FDA Fast Track and Orphan Drug designations. Valion also controls its drug supply through a wholly owned US CDMO, adding operational strength to its development efforts.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You now face a clearer path to FDA approval and domestic supply control for radiation countermeasures with Valion's leadership and manufacturing setup. This opens a near-term opportunity to target US government contracts and explore oncology supportive care with Entolimod.
◆ Coverage
2 sources · 5 Oct 2026
◆ Related on Wire
◆ Topics